Lorraine Laban is an Associate Manager at CBPartners.
Connect with Lorraine Laban
Despite surpassing the challenge of FDA approval, there are now a wide range of implications for health care access and coverage in the U.S for aducanumab, a treatment for Alzheimer's Disease.
Sign up here to receive our monthly newsletter, featuring our latest blog posts, news, and updates.
Copyright © CBPartners. All Rights Reserved.
Site Design & Build by Thinking Juice